Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

This study is testing a new CAR-T cell therapy called GYA01 (CART84) — immune cells engineered to recognize a protein called CD84 on leukemia cells — in adults with relapsed or treatment-resistant acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL), two aggressive blood cancers. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with AML or T-ALL with at least 5% leukemia cells in your bone marrow or blood - Your cancer has not responded to chemotherapy, has relapsed, or came back after a stem cell transplant (at least 3 months prior) - Your leukemia cells test positive for the CD84 protein - You have adequate heart, lung, kidney, and liver function - A potential stem cell donor has been identified for follow-up transplant (if applicable) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active HIV, hepatitis B, or hepatitis C - You have an uncontrolled serious infection - You have a history of significant neurological conditions (epilepsy, recent stroke, severe brain injury, dementia) - You have a serious heart condition (severe heart failure or uncontrolled arrhythmia) - You have an active autoimmune disease requiring treatment in the past 2 years - You have been in another experimental trial within 1 month before treatment - You received a stem cell transplant less than 3 months before planned CART84 infusion Talk to your doctor to see if this trial is right for you.